J
John D. Turnidge
Researcher at University of Adelaide
Publications - 261
Citations - 18486
John D. Turnidge is an academic researcher from University of Adelaide. The author has contributed to research in topics: Antibiotic resistance & Antibacterial agent. The author has an hindex of 69, co-authored 250 publications receiving 16366 citations. Previous affiliations of John D. Turnidge include Women's and Children's Hospital & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Jian Li,Roger L. Nation,John D. Turnidge,Robert W. Milne,Kingsley Coulthard,Kingsley Coulthard,Craig R Rayner,David L. Paterson +7 more
TL;DR: Recent progress in understanding the complex chemistry, pharmacokinetics, and pharmacodynamics of colistin, the interplay between these three aspects, and their effect on the clinical use of this important antibiotic are summarized.
Journal ArticleDOI
Dissemination of New Methicillin-Resistant Staphylococcus aureus Clones in the Community
Keiko Okuma,Kozue Iwakawa,John D. Turnidge,Warren B. Grubb,Jan M. Bell,Frances G. O'Brien,Geoffrey W. Coombs,John W. Pearman,Fred C. Tenover,Maria Kapi,Chuntima Tiensasitorn,Teruyo Ito,Keiichi Hiramatsu +12 more
TL;DR: Multiple methicillin-resistant Staphylococcus aureus clones carrying type IV staphylitiscal cassette chromosome mec were identified in the community-acquired MRSA strains of both the United States and Australia.
Journal ArticleDOI
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Jian Li,Roger L. Nation,Robert L Milne,John D. Turnidge,Kingsley Coulthard,Kingsley Coulthard +5 more
TL;DR: It is likely that colistin will be an important antimicrobial option against multi-resistant Gram-negative bacteria, for some years to come.
Journal ArticleDOI
The Pharmacodynamics of β-Lactams
TL;DR: For example, this paper showed that the time for which drug levels exceed the minimum inhibitory concentration (MIC) correlates best with bacterial eradication, and this is now being borne out in human studies.
Journal ArticleDOI
Setting and Revising Antibacterial Susceptibility Breakpoints
TL;DR: Clinical microbiology laboratories need to communicate results of antibacterial susceptibility testing to prescribers and it is mandatory that breakpoints be reviewed when antibacterial agents have been in clinical use for some time, particularly if mechanisms of bacterial resistance to the drug have been described.